Other News To Note

Capstone Therapeutics, of Tempe, Ariz., is cutting 14 of its 18 full-time employees to preserve cash during ongoing discussions with potential partners for dermal scarring drug AZX100. The company has been struggling since Phase IIa trials fell short of statistical significance last year.